ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hematological Cancers Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-10M6271
Home | Market Reports | Health| Health Conditions| Cancer
Global Hematological Cancers Market Insights and Forecast to 2028
BUY CHAPTERS

Global Hematological Cancers Market Research Report 2025

Code: QYRE-Auto-10M6271
Report
September 2025
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
Hemocue AB
C R Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba Ltd
Diagnocure
Astellas Pharma US
Johnson & Johnson

Hematological Cancers Market Size

The global market for Hematological Cancers was valued at US$ 68580 million in the year 2024 and is projected to reach a revised size of US$ 114080 million by 2031, growing at a CAGR of 7.6% during the forecast period.

Hematological Cancers Market

Hematological Cancers Market

hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hematological Cancers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematological Cancers.
The Hematological Cancers market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hematological Cancers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hematological Cancers companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Hematological Cancers Market Report

Report Metric Details
Report Name Hematological Cancers Market
Accounted market size in year US$ 68580 million
Forecasted market size in 2031 US$ 114080 million
CAGR 7.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Pharmacological Therapies
  • Stem Cell Transplantation
  • Surgery and Radiation Therapy
  • Anemia Treatment
  • Thrombosis Treatment
  • Neutopenia Treatment
  • Symptomatic treatment
Segment by Application
  • Epidemiology
  • Pathophysiology of Leukemic Stem Cells
  • Kidney Diseases
  • Genetic Diseases
  • Other Diseases
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories, Beckman Coulter, HemoCue AB, C. R. Bard, Siemens AG, Sysmex, Mindray Medical International Limited, Bio-Rad Laboratories, The Medicine Company, Pharmacyclics, Horiba, DiagnoCure Inc., Astellas Pharma US
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Hematological Cancers company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hematological Cancers Market growing?

Ans: The Hematological Cancers Market witnessing a CAGR of 7.6% during the forecast period 2025-2031.

What is the Hematological Cancers Market size in 2031?

Ans: The Hematological Cancers Market size in 2031 will be US$ 114080 million.

Who are the main players in the Hematological Cancers Market report?

Ans: The main players in the Hematological Cancers Market are Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories, Beckman Coulter, HemoCue AB, C. R. Bard, Siemens AG, Sysmex, Mindray Medical International Limited, Bio-Rad Laboratories, The Medicine Company, Pharmacyclics, Horiba, DiagnoCure Inc., Astellas Pharma US

What are the Application segmentation covered in the Hematological Cancers Market report?

Ans: The Applications covered in the Hematological Cancers Market report are Epidemiology, Pathophysiology of Leukemic Stem Cells, Kidney Diseases, Genetic Diseases, Other Diseases

What are the Type segmentation covered in the Hematological Cancers Market report?

Ans: The Types covered in the Hematological Cancers Market report are Pharmacological Therapies, Stem Cell Transplantation, Surgery and Radiation Therapy, Anemia Treatment, Thrombosis Treatment, Neutopenia Treatment, Symptomatic treatment

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematological Cancers Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Pharmacological Therapies
1.2.3 Stem Cell Transplantation
1.2.4 Surgery and Radiation Therapy
1.2.5 Anemia Treatment
1.2.6 Thrombosis Treatment
1.2.7 Neutopenia Treatment
1.2.8 Symptomatic treatment
1.3 Market by Application
1.3.1 Global Hematological Cancers Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Epidemiology
1.3.3 Pathophysiology of Leukemic Stem Cells
1.3.4 Kidney Diseases
1.3.5 Genetic Diseases
1.3.6 Other Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hematological Cancers Market Perspective (2020-2031)
2.2 Global Hematological Cancers Growth Trends by Region
2.2.1 Global Hematological Cancers Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Hematological Cancers Historic Market Size by Region (2020-2025)
2.2.3 Hematological Cancers Forecasted Market Size by Region (2026-2031)
2.3 Hematological Cancers Market Dynamics
2.3.1 Hematological Cancers Industry Trends
2.3.2 Hematological Cancers Market Drivers
2.3.3 Hematological Cancers Market Challenges
2.3.4 Hematological Cancers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematological Cancers Players by Revenue
3.1.1 Global Top Hematological Cancers Players by Revenue (2020-2025)
3.1.2 Global Hematological Cancers Revenue Market Share by Players (2020-2025)
3.2 Global Hematological Cancers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Hematological Cancers Revenue
3.4 Global Hematological Cancers Market Concentration Ratio
3.4.1 Global Hematological Cancers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematological Cancers Revenue in 2024
3.5 Global Key Players of Hematological Cancers Head office and Area Served
3.6 Global Key Players of Hematological Cancers, Product and Application
3.7 Global Key Players of Hematological Cancers, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematological Cancers Breakdown Data by Type
4.1 Global Hematological Cancers Historic Market Size by Type (2020-2025)
4.2 Global Hematological Cancers Forecasted Market Size by Type (2026-2031)
5 Hematological Cancers Breakdown Data by Application
5.1 Global Hematological Cancers Historic Market Size by Application (2020-2025)
5.2 Global Hematological Cancers Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Hematological Cancers Market Size (2020-2031)
6.2 North America Hematological Cancers Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Hematological Cancers Market Size by Country (2020-2025)
6.4 North America Hematological Cancers Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hematological Cancers Market Size (2020-2031)
7.2 Europe Hematological Cancers Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Hematological Cancers Market Size by Country (2020-2025)
7.4 Europe Hematological Cancers Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematological Cancers Market Size (2020-2031)
8.2 Asia-Pacific Hematological Cancers Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Hematological Cancers Market Size by Region (2020-2025)
8.4 Asia-Pacific Hematological Cancers Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hematological Cancers Market Size (2020-2031)
9.2 Latin America Hematological Cancers Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Hematological Cancers Market Size by Country (2020-2025)
9.4 Latin America Hematological Cancers Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematological Cancers Market Size (2020-2031)
10.2 Middle East & Africa Hematological Cancers Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Hematological Cancers Market Size by Country (2020-2025)
10.4 Middle East & Africa Hematological Cancers Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Karyopharm Therapeutics
11.1.1 Karyopharm Therapeutics Company Details
11.1.2 Karyopharm Therapeutics Business Overview
11.1.3 Karyopharm Therapeutics Hematological Cancers Introduction
11.1.4 Karyopharm Therapeutics Revenue in Hematological Cancers Business (2020-2025)
11.1.5 Karyopharm Therapeutics Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Hematological Cancers Introduction
11.2.4 Johnson & Johnson Revenue in Hematological Cancers Business (2020-2025)
11.2.5 Johnson & Johnson Recent Development
11.3 Roche Diagnostics A/S
11.3.1 Roche Diagnostics A/S Company Details
11.3.2 Roche Diagnostics A/S Business Overview
11.3.3 Roche Diagnostics A/S Hematological Cancers Introduction
11.3.4 Roche Diagnostics A/S Revenue in Hematological Cancers Business (2020-2025)
11.3.5 Roche Diagnostics A/S Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Details
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Hematological Cancers Introduction
11.4.4 AbbVie Revenue in Hematological Cancers Business (2020-2025)
11.4.5 AbbVie Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Hematological Cancers Introduction
11.5.4 Novartis Revenue in Hematological Cancers Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Kite Pharma
11.6.1 Kite Pharma Company Details
11.6.2 Kite Pharma Business Overview
11.6.3 Kite Pharma Hematological Cancers Introduction
11.6.4 Kite Pharma Revenue in Hematological Cancers Business (2020-2025)
11.6.5 Kite Pharma Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Details
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Hematological Cancers Introduction
11.7.4 Celgene Corporation Revenue in Hematological Cancers Business (2020-2025)
11.7.5 Celgene Corporation Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Details
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Hematological Cancers Introduction
11.8.4 Abbott Laboratories Revenue in Hematological Cancers Business (2020-2025)
11.8.5 Abbott Laboratories Recent Development
11.9 Beckman Coulter
11.9.1 Beckman Coulter Company Details
11.9.2 Beckman Coulter Business Overview
11.9.3 Beckman Coulter Hematological Cancers Introduction
11.9.4 Beckman Coulter Revenue in Hematological Cancers Business (2020-2025)
11.9.5 Beckman Coulter Recent Development
11.10 HemoCue AB
11.10.1 HemoCue AB Company Details
11.10.2 HemoCue AB Business Overview
11.10.3 HemoCue AB Hematological Cancers Introduction
11.10.4 HemoCue AB Revenue in Hematological Cancers Business (2020-2025)
11.10.5 HemoCue AB Recent Development
11.11 C. R. Bard
11.11.1 C. R. Bard Company Details
11.11.2 C. R. Bard Business Overview
11.11.3 C. R. Bard Hematological Cancers Introduction
11.11.4 C. R. Bard Revenue in Hematological Cancers Business (2020-2025)
11.11.5 C. R. Bard Recent Development
11.12 Siemens AG
11.12.1 Siemens AG Company Details
11.12.2 Siemens AG Business Overview
11.12.3 Siemens AG Hematological Cancers Introduction
11.12.4 Siemens AG Revenue in Hematological Cancers Business (2020-2025)
11.12.5 Siemens AG Recent Development
11.13 Sysmex
11.13.1 Sysmex Company Details
11.13.2 Sysmex Business Overview
11.13.3 Sysmex Hematological Cancers Introduction
11.13.4 Sysmex Revenue in Hematological Cancers Business (2020-2025)
11.13.5 Sysmex Recent Development
11.14 Mindray Medical International Limited
11.14.1 Mindray Medical International Limited Company Details
11.14.2 Mindray Medical International Limited Business Overview
11.14.3 Mindray Medical International Limited Hematological Cancers Introduction
11.14.4 Mindray Medical International Limited Revenue in Hematological Cancers Business (2020-2025)
11.14.5 Mindray Medical International Limited Recent Development
11.15 Bio-Rad Laboratories
11.15.1 Bio-Rad Laboratories Company Details
11.15.2 Bio-Rad Laboratories Business Overview
11.15.3 Bio-Rad Laboratories Hematological Cancers Introduction
11.15.4 Bio-Rad Laboratories Revenue in Hematological Cancers Business (2020-2025)
11.15.5 Bio-Rad Laboratories Recent Development
11.16 The Medicine Company
11.16.1 The Medicine Company Company Details
11.16.2 The Medicine Company Business Overview
11.16.3 The Medicine Company Hematological Cancers Introduction
11.16.4 The Medicine Company Revenue in Hematological Cancers Business (2020-2025)
11.16.5 The Medicine Company Recent Development
11.17 Pharmacyclics
11.17.1 Pharmacyclics Company Details
11.17.2 Pharmacyclics Business Overview
11.17.3 Pharmacyclics Hematological Cancers Introduction
11.17.4 Pharmacyclics Revenue in Hematological Cancers Business (2020-2025)
11.17.5 Pharmacyclics Recent Development
11.18 Horiba
11.18.1 Horiba Company Details
11.18.2 Horiba Business Overview
11.18.3 Horiba Hematological Cancers Introduction
11.18.4 Horiba Revenue in Hematological Cancers Business (2020-2025)
11.18.5 Horiba Recent Development
11.19 DiagnoCure Inc.
11.19.1 DiagnoCure Inc. Company Details
11.19.2 DiagnoCure Inc. Business Overview
11.19.3 DiagnoCure Inc. Hematological Cancers Introduction
11.19.4 DiagnoCure Inc. Revenue in Hematological Cancers Business (2020-2025)
11.19.5 DiagnoCure Inc. Recent Development
11.20 Astellas Pharma US
11.20.1 Astellas Pharma US Company Details
11.20.2 Astellas Pharma US Business Overview
11.20.3 Astellas Pharma US Hematological Cancers Introduction
11.20.4 Astellas Pharma US Revenue in Hematological Cancers Business (2020-2025)
11.20.5 Astellas Pharma US Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
Hemocue AB
C R Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba Ltd
Diagnocure
Astellas Pharma US
Johnson & Johnson
List of Tables
 Table 1. Global Hematological Cancers Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Pharmacological Therapies
 Table 3. Key Players of Stem Cell Transplantation
 Table 4. Key Players of Surgery and Radiation Therapy
 Table 5. Key Players of Anemia Treatment
 Table 6. Key Players of Thrombosis Treatment
 Table 7. Key Players of Neutopenia Treatment
 Table 8. Key Players of Symptomatic treatment
 Table 9. Global Hematological Cancers Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Hematological Cancers Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 11. Global Hematological Cancers Market Size by Region (2020-2025) & (US$ Million)
 Table 12. Global Hematological Cancers Market Share by Region (2020-2025)
 Table 13. Global Hematological Cancers Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 14. Global Hematological Cancers Market Share by Region (2026-2031)
 Table 15. Hematological Cancers Market Trends
 Table 16. Hematological Cancers Market Drivers
 Table 17. Hematological Cancers Market Challenges
 Table 18. Hematological Cancers Market Restraints
 Table 19. Global Hematological Cancers Revenue by Players (2020-2025) & (US$ Million)
 Table 20. Global Hematological Cancers Market Share by Players (2020-2025)
 Table 21. Global Top Hematological Cancers Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Cancers as of 2024)
 Table 22. Ranking of Global Top Hematological Cancers Companies by Revenue (US$ Million) in 2024
 Table 23. Global 5 Largest Players Market Share by Hematological Cancers Revenue (CR5 and HHI) & (2020-2025)
 Table 24. Global Key Players of Hematological Cancers, Headquarters and Area Served
 Table 25. Global Key Players of Hematological Cancers, Product and Application
 Table 26. Global Key Players of Hematological Cancers, Date of Enter into This Industry
 Table 27. Mergers & Acquisitions, Expansion Plans
 Table 28. Global Hematological Cancers Market Size by Type (2020-2025) & (US$ Million)
 Table 29. Global Hematological Cancers Revenue Market Share by Type (2020-2025)
 Table 30. Global Hematological Cancers Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 31. Global Hematological Cancers Revenue Market Share by Type (2026-2031)
 Table 32. Global Hematological Cancers Market Size by Application (2020-2025) & (US$ Million)
 Table 33. Global Hematological Cancers Revenue Market Share by Application (2020-2025)
 Table 34. Global Hematological Cancers Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 35. Global Hematological Cancers Revenue Market Share by Application (2026-2031)
 Table 36. North America Hematological Cancers Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. North America Hematological Cancers Market Size by Country (2020-2025) & (US$ Million)
 Table 38. North America Hematological Cancers Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Europe Hematological Cancers Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Europe Hematological Cancers Market Size by Country (2020-2025) & (US$ Million)
 Table 41. Europe Hematological Cancers Market Size by Country (2026-2031) & (US$ Million)
 Table 42. Asia-Pacific Hematological Cancers Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Asia-Pacific Hematological Cancers Market Size by Region (2020-2025) & (US$ Million)
 Table 44. Asia-Pacific Hematological Cancers Market Size by Region (2026-2031) & (US$ Million)
 Table 45. Latin America Hematological Cancers Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Latin America Hematological Cancers Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Latin America Hematological Cancers Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Middle East & Africa Hematological Cancers Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 49. Middle East & Africa Hematological Cancers Market Size by Country (2020-2025) & (US$ Million)
 Table 50. Middle East & Africa Hematological Cancers Market Size by Country (2026-2031) & (US$ Million)
 Table 51. Karyopharm Therapeutics Company Details
 Table 52. Karyopharm Therapeutics Business Overview
 Table 53. Karyopharm Therapeutics Hematological Cancers Product
 Table 54. Karyopharm Therapeutics Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 55. Karyopharm Therapeutics Recent Development
 Table 56. Johnson & Johnson Company Details
 Table 57. Johnson & Johnson Business Overview
 Table 58. Johnson & Johnson Hematological Cancers Product
 Table 59. Johnson & Johnson Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 60. Johnson & Johnson Recent Development
 Table 61. Roche Diagnostics A/S Company Details
 Table 62. Roche Diagnostics A/S Business Overview
 Table 63. Roche Diagnostics A/S Hematological Cancers Product
 Table 64. Roche Diagnostics A/S Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 65. Roche Diagnostics A/S Recent Development
 Table 66. AbbVie Company Details
 Table 67. AbbVie Business Overview
 Table 68. AbbVie Hematological Cancers Product
 Table 69. AbbVie Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 70. AbbVie Recent Development
 Table 71. Novartis Company Details
 Table 72. Novartis Business Overview
 Table 73. Novartis Hematological Cancers Product
 Table 74. Novartis Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 75. Novartis Recent Development
 Table 76. Kite Pharma Company Details
 Table 77. Kite Pharma Business Overview
 Table 78. Kite Pharma Hematological Cancers Product
 Table 79. Kite Pharma Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 80. Kite Pharma Recent Development
 Table 81. Celgene Corporation Company Details
 Table 82. Celgene Corporation Business Overview
 Table 83. Celgene Corporation Hematological Cancers Product
 Table 84. Celgene Corporation Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 85. Celgene Corporation Recent Development
 Table 86. Abbott Laboratories Company Details
 Table 87. Abbott Laboratories Business Overview
 Table 88. Abbott Laboratories Hematological Cancers Product
 Table 89. Abbott Laboratories Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 90. Abbott Laboratories Recent Development
 Table 91. Beckman Coulter Company Details
 Table 92. Beckman Coulter Business Overview
 Table 93. Beckman Coulter Hematological Cancers Product
 Table 94. Beckman Coulter Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 95. Beckman Coulter Recent Development
 Table 96. HemoCue AB Company Details
 Table 97. HemoCue AB Business Overview
 Table 98. HemoCue AB Hematological Cancers Product
 Table 99. HemoCue AB Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 100. HemoCue AB Recent Development
 Table 101. C. R. Bard Company Details
 Table 102. C. R. Bard Business Overview
 Table 103. C. R. Bard Hematological Cancers Product
 Table 104. C. R. Bard Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 105. C. R. Bard Recent Development
 Table 106. Siemens AG Company Details
 Table 107. Siemens AG Business Overview
 Table 108. Siemens AG Hematological Cancers Product
 Table 109. Siemens AG Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 110. Siemens AG Recent Development
 Table 111. Sysmex Company Details
 Table 112. Sysmex Business Overview
 Table 113. Sysmex Hematological Cancers Product
 Table 114. Sysmex Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 115. Sysmex Recent Development
 Table 116. Mindray Medical International Limited Company Details
 Table 117. Mindray Medical International Limited Business Overview
 Table 118. Mindray Medical International Limited Hematological Cancers Product
 Table 119. Mindray Medical International Limited Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 120. Mindray Medical International Limited Recent Development
 Table 121. Bio-Rad Laboratories Company Details
 Table 122. Bio-Rad Laboratories Business Overview
 Table 123. Bio-Rad Laboratories Hematological Cancers Product
 Table 124. Bio-Rad Laboratories Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 125. Bio-Rad Laboratories Recent Development
 Table 126. The Medicine Company Company Details
 Table 127. The Medicine Company Business Overview
 Table 128. The Medicine Company Hematological Cancers Product
 Table 129. The Medicine Company Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 130. The Medicine Company Recent Development
 Table 131. Pharmacyclics Company Details
 Table 132. Pharmacyclics Business Overview
 Table 133. Pharmacyclics Hematological Cancers Product
 Table 134. Pharmacyclics Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 135. Pharmacyclics Recent Development
 Table 136. Horiba Company Details
 Table 137. Horiba Business Overview
 Table 138. Horiba Hematological Cancers Product
 Table 139. Horiba Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 140. Horiba Recent Development
 Table 141. DiagnoCure Inc. Company Details
 Table 142. DiagnoCure Inc. Business Overview
 Table 143. DiagnoCure Inc. Hematological Cancers Product
 Table 144. DiagnoCure Inc. Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 145. DiagnoCure Inc. Recent Development
 Table 146. Astellas Pharma US Company Details
 Table 147. Astellas Pharma US Business Overview
 Table 148. Astellas Pharma US Hematological Cancers Product
 Table 149. Astellas Pharma US Revenue in Hematological Cancers Business (2020-2025) & (US$ Million)
 Table 150. Astellas Pharma US Recent Development
 Table 151. Research Programs/Design for This Report
 Table 152. Key Data Information from Secondary Sources
 Table 153. Key Data Information from Primary Sources
 Table 154. Authors List of This Report


List of Figures
 Figure 1. Hematological Cancers Picture
 Figure 2. Global Hematological Cancers Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Hematological Cancers Market Share by Type: 2024 VS 2031
 Figure 4. Pharmacological Therapies Features
 Figure 5. Stem Cell Transplantation Features
 Figure 6. Surgery and Radiation Therapy Features
 Figure 7. Anemia Treatment Features
 Figure 8. Thrombosis Treatment Features
 Figure 9. Neutopenia Treatment Features
 Figure 10. Symptomatic treatment Features
 Figure 11. Global Hematological Cancers Market Size by Application (2020-2031) & (US$ Million)
 Figure 12. Global Hematological Cancers Market Share by Application: 2024 VS 2031
 Figure 13. Epidemiology Case Studies
 Figure 14. Pathophysiology of Leukemic Stem Cells Case Studies
 Figure 15. Kidney Diseases Case Studies
 Figure 16. Genetic Diseases Case Studies
 Figure 17. Other Diseases Case Studies
 Figure 18. Hematological Cancers Report Years Considered
 Figure 19. Global Hematological Cancers Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 20. Global Hematological Cancers Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 21. Global Hematological Cancers Market Share by Region: 2024 VS 2031
 Figure 22. Global Hematological Cancers Market Share by Players in 2024
 Figure 23. Global Top Hematological Cancers Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Cancers as of 2024)
 Figure 24. The Top 10 and 5 Players Market Share by Hematological Cancers Revenue in 2024
 Figure 25. North America Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. North America Hematological Cancers Market Share by Country (2020-2031)
 Figure 27. United States Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Canada Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Europe Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Hematological Cancers Market Share by Country (2020-2031)
 Figure 31. Germany Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. France Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. U.K. Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Italy Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Russia Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Nordic Countries Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Hematological Cancers Market Share by Region (2020-2031)
 Figure 39. China Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Japan Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. South Korea Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. India Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Australia Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Latin America Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Latin America Hematological Cancers Market Share by Country (2020-2031)
 Figure 47. Mexico Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Brazil Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Middle East & Africa Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Middle East & Africa Hematological Cancers Market Share by Country (2020-2031)
 Figure 51. Turkey Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. UAE Hematological Cancers Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. Karyopharm Therapeutics Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 55. Johnson & Johnson Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 56. Roche Diagnostics A/S Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 57. AbbVie Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 58. Novartis Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 59. Kite Pharma Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 60. Celgene Corporation Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 61. Abbott Laboratories Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 62. Beckman Coulter Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 63. HemoCue AB Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 64. C. R. Bard Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 65. Siemens AG Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 66. Sysmex Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 67. Mindray Medical International Limited Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 68. Bio-Rad Laboratories Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 69. The Medicine Company Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 70. Pharmacyclics Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 71. Horiba Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 72. DiagnoCure Inc. Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 73. Astellas Pharma US Revenue Growth Rate in Hematological Cancers Business (2020-2025)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Hematologic Malignancies Treatment Market Research Report 2024
Global Hematologic Oncology Treatment Market Research Report 2024
Global Blood Tumor Treatment Market Research Report 2024
Global Blood Tumor Drugs Market Research Report 2024
Global Blood Cancer Treatments Market Research Report 2024
Blood Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Blood and Bone Marrow Cancer Treatment Market Insights Forecast to 2030
Global Blood Cancer Therapeutics Market Insights Forecast to 2030
Hematology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematology Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematologic Malignancies Detection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug for Blood Cancers Market Research Report 2024
Drugs for Hematology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lymphoma Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
B Cell Non Hodgkin s Lymphoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hematology Oncology Diagnostics Market Research Report 2024
Blood Cancer Detection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Myeloma Treatment Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions